title: The effect of extended post-discharge chemical thromboprophylaxis on venous thromboembolism rates after bariatric surgery: a prospective comparison trial.
abstract: BACKGROUND
  The effect of extended post-discharge thromboprophylaxis (ETP) on venous thromboembolism (VTE) rates following bariatric surgery (BS) is unknown.
  
  
  METHODS
  308 consecutive patients who underwent BS between 2003 and 2007 and who had > 1 month of follow-up were included. In-hospital-only VTE prophylaxis (group A), or extended 10-day ETP (group B) was used in 132 and 176 patients, respectively. All patients underwent bilateral lower extremity venous Doppler studies (BLEVDS) prior to discharge. Primary endpoint was the incidence of VTE within 30 days postoperatively. VTE was defined as a clinically evident deep vein thrombosis or pulmonary embolism documented by positive BLEVDS, or computed chest tomography. The primary safety endpoint was bleeding associated with > or = 2 g/dL decrease in hemoglobin compared with baseline, transfusion or reoperation.
  
  
  RESULTS
  The incidence of VTE was 1.9% (6/308); 66.6% (4/6) of cases occurred after cessation of thromboprophylaxis. There were no deaths in either group. With the exception of percentage open surgical approach (A: 3% versus B: 0%, p = 0.03), percentage conversions (A: 0 versus B: 3.8%, p = 0.01), and hospital stay (A: 3 versus B: 2.2 days, p < 0.0001), the two groups were comparable in relation to age, sex, body mass index, percentage revision surgery, operative time, and history of VTE. VTE rate was significantly higher in group A (A: 4.5% versus B: 0%, p = 0.006). Although morbidity was higher in group A (A: 12.1% versus B: 1.1%, p < 0.0001), no VTE event occurred in patients who had other complications. The incidence of significant bleeding was lower in group B (A: 5.3% versus B: 0.56%, p = 0.02).
  
  
  CONCLUSIONS
  ETP is safe and effective in reducing the incidence of VTE as compared with in-hospital thromboprophylaxis only.
authors.affiliation: Bariatric Surgery Center, St Francis Hospital and Medical Center, University of Connecticut, 114 Woodland Street, Hartford, CT 06105, USA. IRaftopo@stfranciscare.org
authors.forename: Ioannis
authors.initials: I
authors.lastname: Raftopoulos
authors.forename: Carolyn
authors.initials: C
authors.lastname: Martindale
authors.forename: Andrea
authors.initials: A
authors.lastname: Cronin
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Steinberg
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D050110:Bariatric Surgery / Q000009:adverse effects*; D017984:Enoxaparin / Q000008:administration & dosage*; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006801:Humans; D015994:Incidence; D010535:Laparoscopy; D007866:Leg / Q000098:blood supply / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D009767:Obesity, Morbid / Q000601:surgery*; D011446:Prospective Studies; D012086:Reoperation; D012307:Risk Factors; D016896:Treatment Outcome; D018608:Ultrasonography, Doppler; D054556:Venous Thromboembolism / Q000000981:diagnostic imaging / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*
chemical_list: D017984:Enoxaparin; D005343:Fibrinolytic Agents